Clinical Trials
98 trialsNCT04301076 2026-05-13
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
National Cancer Institute (NCI)
Phase 1 Suspended
NCT07444710 2026-05-13
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT02123758 2026-05-08
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 1 Active not recruiting
NCT04577833 2026-05-08
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04662580 2026-05-08
ARX517
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05818683 2026-05-08
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT04872790 2026-05-06
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
OHSU Knight Cancer Institute
Phase 1 Active not recruiting
NCT03816332 2026-04-30
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04739813 2026-04-29
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT05389423 2026-04-28
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT02913196 2026-04-20
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
Weill Medical College of Cornell University
Phase 1 Completed
NCT04884035 2026-04-17
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Celgene
Phase 1 Recruiting
NCT03220022 2026-04-13
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06421935 2026-03-24
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
EMD Serono
Phase 1 Active not recruiting
NCT03819296 2026-03-11
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05157971 2026-03-05
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
City of Hope Medical Center
Phase 1 Recruiting
NCT04231877 2026-03-03
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
University of Washington
Phase 1 Recruiting
NCT07339267 2026-02-18
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
Astellas Pharma Inc
Phase 1 Recruiting
NCT02776436 2026-02-17
REDEX
Leiden University Medical Center
Phase 1 Completed
NCT04850495 2026-02-06
Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Suspended
NCT04729114 2026-02-04
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Astellas Pharma Inc
Phase 1 Recruiting
NCT04323956 2026-02-02
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
Mayo Clinic
Phase 1 Active not recruiting
NCT01695005 2025-12-26
A Study of LY3039478 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT07278856 2025-12-12
Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
City of Hope Medical Center
Phase 1 Not yet recruiting
NCT04477512 2025-11-12
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
Washington University School of Medicine
Phase 1 Completed
NCT03595917 2025-11-04
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05270057 2025-10-09
LONCA
Medical College of Wisconsin
Phase 1 Active not recruiting
NCT05276492 2025-10-03
Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.
University of Chicago
Phase 1 Terminated
NCT04666129 2025-08-17
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT05279300 2025-08-11
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
CStone Pharmaceuticals
Phase 1 Recruiting
NCT06977711 2025-08-05
Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
The University of Texas Health Science Center at San Antonio
Phase 1 Recruiting
NCT03742258 2025-06-18
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Northwestern University
Phase 1 Completed
NCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT06251180 2025-03-25
Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1 Recruiting
NCT03792256 2025-03-21
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Children's Oncology Group
Phase 1 Completed
NCT01792687 2025-03-04
Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
Aragon Pharmaceuticals, Inc.
Phase 1 Completed
NCT04599634 2025-02-04
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT05295927 2025-02-03
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Janssen Research & Development, LLC
Phase 1 Terminated
NCT03467373 2025-01-17
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
Hoffmann-La Roche
Phase 1 Completed
NCT06566989 2024-10-23
MK-5684-008
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT04291664 2024-10-17
PK and Dose Escalation and Expansion Study of DST-2970
DisperSol Technologies, LLC
Phase 1 Terminated
NCT06554639 2024-10-15
MK-5684-011
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT05084859 2024-08-09
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Biosplice Therapeutics, Inc.
Phase 1 Terminated
NCT01523977 2024-07-18
CRAD001NUS175T
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04790903 2024-07-11
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 1 Terminated
NCT04933617 2024-07-09
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT04726332 2024-05-14
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
Exelixis
Phase 1 Terminated
NCT04677855 2024-04-10
Study of PCUR-101 in Combination With ADT in Patients With mCRPC
Pellficure Pharmaceuticals, Inc
Phase 1 Terminated
NCT04083898 2024-03-19
Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma
Washington University School of Medicine
Phase 1 Terminated
NCT04548700 2024-03-07
Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Terminated